PARIS (Reuters) – Healthcare and clinical diagnostics company Novacyt, whose shares have surged on the back of its COVID-19 testing products, announced on Thursday the launch of three new products to support testing for the presence of the virus.
Novacyt, whose Paris-listed shares are up nearly 1,500% since the start of 2020, said its new products were ‘Exsig Direct’, ‘Exsig Mag’ and ‘COVID-HT’.
“As we continue to supply our COVID-19 test to laboratories around the world, we are delighted to provide further support through the launch of these new products,” said Novacyt CEO Graham Mullis.
(Reporting by Sudip Kar-Gupta; Editing by Mark Potter)
